Amgen (NASDAQ:AMGN) Price Target Raised to $370.00 at Royal Bank Of Canada

Amgen (NASDAQ:AMGN) had its price target lifted by Royal Bank Of Canada from $360.00 to $370.00 in a research note issued to investors on Tuesday morning,MarketScreener reports. They currently have an outperform rating on the medical research company’s stock.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a research report on Tuesday, January 20th. Cantor Fitzgerald boosted their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Finally, Mizuho boosted their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $355.00.

Amgen Price Performance

Amgen stock opened at $340.00 on Tuesday. Amgen has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm’s 50-day simple moving average is $363.28 and its 200 day simple moving average is $334.04. The firm has a market capitalization of $183.28 billion, a PE ratio of 23.89, a P/E/G ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the previous year, the firm earned $5.31 EPS. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.0%. Amgen’s payout ratio is presently 70.84%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Old North State Trust LLC increased its stake in shares of Amgen by 21.6% during the 4th quarter. Old North State Trust LLC now owns 2,568 shares of the medical research company’s stock valued at $841,000 after acquiring an additional 456 shares during the last quarter. J. Derek Lewis & Associates Inc. acquired a new position in shares of Amgen during the 4th quarter valued at about $269,000. Purpose Unlimited Inc. acquired a new position in shares of Amgen during the 4th quarter valued at about $1,299,000. Cornerstone Planning LLC acquired a new position in shares of Amgen during the 4th quarter valued at about $2,155,000. Finally, Rockefeller Capital Management L.P. increased its stake in shares of Amgen by 27.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 642,161 shares of the medical research company’s stock valued at $210,186,000 after acquiring an additional 138,577 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 win — Amgen’s subcutaneous TEPEZZA met primary and key secondary endpoints (77% proptosis response, clinically meaningful ≥3 mm reduction), matching IV efficacy and offering faster dosing that could broaden access. AMGN’s Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
• Positive Sentiment: Analyst support — RBC Capital raised its price target to $370 and kept an Outperform rating, signaling institutional confidence in Amgen’s commercial prospects for TEPEZZA. RBC raises AMGN price target to $370
• Neutral Sentiment: Market interest rising — Retail and institutional attention to AMGN has increased (search/coverage pieces from Zacks/Yahoo), which can amplify intraday moves but is not a directional catalyst by itself. Investors Heavily Search Amgen Inc. (AMGN)
• Neutral Sentiment: Competitive read — Stifel notes Amgen’s topline compares favorably to Viridian’s data on absolute and placebo‑adjusted response, but highlights that Viridian’s subcutaneous injection profile could still differentiate in the market—keeping competitive uncertainty alive. Stifel sees path towards differentiation for Viridian after Amgen data
• Negative Sentiment: Stock weakness despite data — Multiple reports note Amgen shares fell intraday even after the positive TEPEZZA readout; investors may be taking profits, weighing execution/commercialization risk, or reacting to remaining competitive questions. Amgen Posts 77% Response In Thyroid Eye Disease Study

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.